The historical rank and industry rank for Swedish Orphan Biovitrum AB's Net Margin % or its related term are showing as below:
MEX:SOBI N'
s Net Margin % Range Over the Past 10 Years
Min: 1.69 Med: 16.33 Max: 26.46
Current: 3.18
MEX:SOBI N's Net Margin % is ranked worse than 57.5% of 953
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs MEX:SOBI N: 3.18
Swedish Orphan Biovitrum AB (MEX:SOBI N) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Swedish Orphan Biovitrum AB Net Margin % Related Terms
Swedish Orphan Biovitrum AB Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (MEX:SOBI N) has a Net Margin % of 18.35% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Swedish Orphan Biovitrum AB and its competitors. This is 12% above median its historical median of 16.33. Over the past decade, Swedish Orphan Biovitrum AB's Net Margin % has ranged from 1.69 to 26.46. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #548 out of 953 companies in the Drug Manufacturers industry, placing it in the top 57.5%.
Is Swedish Orphan Biovitrum AB's Net Margin % too high?
Swedish Orphan Biovitrum AB's current Net Margin % of 18.35% is 12% above median its 10-year median of 16.33. Over the past 10 years, this metric has ranged from a low of 1.69 to a high of 26.46. The Drug Manufacturers industry median Net Margin % is 5.69. Swedish Orphan Biovitrum AB's value of 18.35% is 222.5% above this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #548 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #548 out of 953 companies for Net Margin %. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median Net Margin % is 5.69. Swedish Orphan Biovitrum AB's value of 18.35% is 222.5% above this benchmark. Historically, Swedish Orphan Biovitrum AB's own Net Margin % has ranged from 1.69 to 26.46 over the past decade. While the company's 10-year median is 16.33 vs. the industry median of 5.69, Swedish Orphan Biovitrum AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current Net Margin % of 18.35% is 222.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Swedish Orphan Biovitrum AB and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Net Margin % is 18.35%, which is 12% above median its own 10-year median of 16.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Swedish Orphan Biovitrum AB (MEX:SOBI N) has a current Net Margin % of 18.35%. The stock's GF Value™ is MXN384.98, compared to a current price of MXN523.55 — trading 36% above its estimated fair value. The current Net Margin % is 18.35%, which is 12% above median its 10-year median of 16.33 and 222.5% above the Drug Manufacturers industry median of 5.69. Swedish Orphan Biovitrum AB's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (MEX:SOBI N), the current Net Margin % is 18.35% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (MEX:SOBI N) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of MXN523.55 is trading 36% above its estimated GF Value™ of MXN384.98.
Key valuation signals for MEX:SOBI N:
Net Margin %: 18.35% (12% above median its 10-year median of 16.33)
GF Value™: MXN384.98 vs. price of MXN523.55 (36% above fair value)
Industry Position: 222.5% above the Drug Manufacturers median (#548 of 953)
No single metric tells the full story. See the MEX:SOBI N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
86GF Score
Get the complete analysis for MEX:SOBI N
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SOBI N has been successfully added to your 
